Osteoporosis is a skeletal disorder and is the leading cause of fractures in the USA. This knowledge can be applied in the development of future therapeutics for osteoporosis. Conclusion: CK2.3 is a novel peptide that drives osteogenesis, and we detailed the molecular sequence of events that are triggered from the stimulation of CK2.3 until the induction of mineralization. Furthermore, CK2.3 induced BMP signaling depends on ERK1/2 and Smad1/5/8 signaling pathways. CK2.3 stimulation induced time dependent release of CK2β from BMPRIA and concurrently CK2.3 colocalized with CK2α. Results: Using these methods, we showed that CK2.3 stimulation activated OSX, ALP, and OCN. We then confirmed the results in primary BMSCs. Methods: Using a newly developed fluorescent CK2.3 analog, specific inhibitors for the BMP signaling pathways, Western blot, and RT-qPCR, we determined the mechanism of CK2.3 in C2C12 cells. However, the detailed signaling pathways, the time frame of signaling, and genes activated remain largely unknown. It induces osteogenesis and bone formation in vitro and in vivo by acting downstream of BMPRIA through releasing CK2 from the receptor. CK2.3, a novel peptide, may be a potential therapeutic. Background: Osteoporosis is a degenerative skeletal disease with a limited number of treatment options.
0 kommentar(er)
